Eric Raefsky
Overview
Explore the profile of Eric Raefsky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
157
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yardley D, Raefsky E, Hainsworth J, Burris 3rd H, Priego V, Inclan A
Breast Cancer Res Treat
. 2014 Nov;
148(3):535-40.
PMID: 25374098
Amrubicin is a synthetic anthracycline which has been shown in preclinical studies to have broad-spectrum anti-tumor activity and a lower potential for cardiotoxicity as compared to doxorubicin. We conducted a...
2.
Yardley D, Raefsky E, Castillo R, Lahiry A, LoCicero R, Thompson D, et al.
Clin Breast Cancer
. 2011 Jul;
11(5):297-305.
PMID: 21729666
Purpose: Neoadjuvant treatment with chemotherapy plus trastuzumab is standard care for women with locally advanced, HER2-positive (HER2(+)) breast cancer. HER2 has been shown to stimulate angiogenesis through vascular endothelial growth...
3.
Yardley D, Burris 3rd H, Peacock N, Raefsky E, Melnik M, Inhorn R, et al.
Breast Cancer Res Treat
. 2010 Jul;
123(2):471-5.
PMID: 20658263
nab-Paclitaxel has shown favorable efficacy and toxicity profiles compared to other taxanes in the treatment of metastatic breast cancer. In this pilot trial, we evaluated a nab-paclitaxel-containing adjuvant regimen in...
4.
Spigel D, Hainsworth J, Yardley D, Raefsky E, Patton J, Peacock N, et al.
J Clin Oncol
. 2009 Nov;
28(1):43-8.
PMID: 19901100
PURPOSE Tracheoesophageal fistulae are rare complications of thoracic cancers and their treatments. Novel antiangiogenic agents in cancer treatment such as bevacizumab potentially impact wound healing and may contribute to tracheoesophageal...
5.
Hainsworth J, Vazquez E, Spigel D, Raefsky E, Bearden J, Saez R, et al.
Cancer
. 2008 Jan;
112(6):1288-95.
PMID: 18189296
Background: The purpose of the current study was to evaluate the efficacy and toxicity of the combination of fludarabine and rituximab, followed by alemtuzumab, as first-line treatment for patients with...
6.
Jones S, Hainsworth J, Burris 3rd H, Thompson D, Raefsky E, Johnson V, et al.
Invest New Drugs
. 2002 May;
20(1):55-61.
PMID: 12008664
This phase I study was conducted to determine the dose limiting toxicity, maximum tolerated doses, and recommended phase II doses of the combination of JM-216 and paclitaxel. Patients received paclitaxel...